Clinical Trial Update: A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. [Phase 2]

View source ↗

Summary

A Phase 2 trial update comparing Tarafenacin at 0.2 mg and 0.4 mg with placebo in patients with Overactive Bladder to evaluate efficacy and tolerability. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Tarafenacin 0.2 mg (Tarafenacin)
• Tarafenacin 0.4 mg (Tarafenacin)

Snippet

Sponsor: Kwang Dong Pharmaceutical co., ltd. | Conditions: Overactive Bladder | Phase 2 | Status: COMPLETED